Primary Outcome
At 2 weeks, the response rate was significantly higher in the group treated with esketamine than in participants in the midazolam control group (10 participants [66.7%] vs 1 participants [6.7%]; OR, 28.00; 95% CI, 2.82 to 277.96). Significant between-group differences were also observed at other visits, including 1, 4, and 6 weeks (